Know Cancer

or
forgot password

Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma


Phase 2
18 Years
N/A
Not Enrolling
Female
Ovarian Carcinoma, Primary Peritoneal Carcinoma

Thank you

Trial Information

Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma


Inclusion Criteria:



- Recurrent ovarian or peritoneal cancer

Exclusion Criteria:

- No prior chemotherapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and Efficacy

Principal Investigator

David M Kushner, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wisconsin, Madison

Authority:

United States: Food and Drug Administration

Study ID:

CO 02701

NCT ID:

NCT00214058

Start Date:

August 2002

Completion Date:

February 2006

Related Keywords:

  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma
  • Carcinoma
  • Ovarian Neoplasms
  • Neoplasms, Glandular and Epithelial

Name

Location

University of Wisconsin Hospital and Clinics Madison, Wisconsin  53792-0001